Journal article: Validation of Milliflex quantum for bioburden testing of pharmaceutical products
Pharmaceutical drug products must fulfill specified quality criteria regarding their microbial content in order to ensure patient safety. Drugs that are delivered into the body via injection, infusion, or implantation must be sterile (i.e., devoid of living microorganisms).
Bioburden testing measures the levels of microbes present in the bulk solution of a drug before sterilization, and thus it provides important information for manufacturing a safe product. In general, bioburden testing has to be performed using the methods described in the pharmacopoeias (membrane filtration or plate count). These methods are well established and validated regarding their effectiveness; however, the incubation time required to visually identify microbial colonies is long.
Register below to read the full article published in the PDA Journal of Pharmaceutical Science and Technology to learn from a leading pharma company about their validation methods and results.
Please read and download the full Journal Article below:15 Journal - Validation of Milliflex Quantum for bioburden testing of pharmaceutical ...
Related content from this organisation
- DRC rejects clinical trial for experimental Ebola vaccine
- Suspected counterfeit vaccines seized in Hong Kong
- Judge overrules Trump effort to advertise drug prices
- On-demand webinar: Increasing Efficiency in the Pharma Analytical Workflow through Standards and Reference Materials
- Article: Tips & tricks: sensitivity gains in LC-MS